Exec-Edge – Page 52 – ExecEdge

Duckhorn Acquired by Butterfly Equity at $1.95 Billion

Duckhorn Acquired by Butterfly Equity at $1.95 Billion

By Karen Roman Winemaker The Duckhorn Portfolio, Inc. (NYSE: NAPA) said it will be taken private in an all-cash deal worth $1.95 billion by Butterfly Equity, in a transaction expected to conclude this winter. The private equity firm agreed to...

Eliem Therapeutics Changes Name to Climb Bio

Eliem Therapeutics Changes Name to Climb Bio

By Karen Roman Eliem Therapeutics, Inc. (Nasdaq: ELYM) said its new corporate name will be Climb Bio, Inc. and it will start trading at Nasdaq with the ticker symbol “CLYM” on Oct. 3. This rebranding reflects Climb’s laser-focused mission on...

Vivani Medical to Test Implant in Obese and Overweight Patients

Vivani Medical to Test Implant in Obese and Overweight Patients

By Daniella Parra Vivani Medical said it received regulatory approval in Australia for its GLP-1 (exenatide) implant, aimed at treating obese and overweight individuals. The trial will evaluate the safety, tolerability and pharmacokinetic profile of the implant, which is designed...

65 Equity Partners Completes Minority Investment in Kendra Scott

65 Equity Partners Completes Minority Investment in Kendra Scott

By Karen Roman 65 Equity Partners said it completed a minority investment in lifestyle and accessories brand Kendra Scott Design. The partnership will contribute to the brand’s cultural collaborations and global expansion into new categories, it said in a statement....

Agendia Study Reaches Milestone for Breast Cancer Research

Agendia Study Reaches Milestone for Breast Cancer Research

By Daniella Parra Agendia said its FLEX Study has enrolled over 17,000 early-stage breast cancer patients from diverse ethnic and racial backgrounds, aiming to address racial and ethnic disparities in breast cancer treatment. The study is a large-scale, real-world evidence,...

Input your search keywords and press Enter.